Trials show positive results in severe asthma for AstraZeneca's biologic medicine
AstraZeneca’s first biologic respiratory medicine met primary and key secondary endpoints in pivotal trials for severe asthma.
AstraZeneca completes commercialisation agreement with Aspen for anaesthetics portfolio
AstraZeneca announced that it has completed* the commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US.
AstraZeneca to sell small molecule antibiotics business to Pfizer
AstraZeneca today announced that it has entered into an agreement with Pfizer Inc. to sell the commercialisation and development rights to its late-stage small molecule antibiotics business in most markets globally outside the US*.
AstraZeneca receives approval in the EU for Type 2 diabetes medicine
AstraZeneca announced that the European Commission (EC) has approved Qtern (saxagliptin/dapagliflozin) tablets for the treatment of type 2 diabetes in all 28 EU member countries plus Iceland, Liechtenstein and Norway. The fixed-dose combination of saxagliptin and dapagliflozin is the first DPP-4i/SGLT-2i combination product to be approved in Europe.
New antibiotic Zavicefta approved in the EU for patients with serious bacterial infections
AstraZeneca has announced that the European Commission (EC) has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a new combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation.
MRC Technology and AstraZeneca call for epigenetic targets in respiratory disease
MRC Technology (MRCT), a medical research charity, and AstraZeneca, a global biopharmaceutical company, are launching an initiative to find new epigenetic drug targets in respiratory disease. MRCT and AstraZeneca are now seeking academics with relevant epigenetics targets to collaborate with them to develop novel treatments for respiratory diseases, which affect millions of people every year.
AstraZeneca presents positive new data on treatment for lupus disease
AstraZeneca and its global biologics research and development arm, MedImmune, announced that they will present positive new data on anifrolumab, an investigational monoclonal antibody that blocks all type 1 interferons, being developed to treat moderate to severe systemic lupus erythematosus (SLE, or lupus), at the Annual European Congress of Rheumatology (EULAR 2016), taking place in London this…
AstraZeneca presents latest data for ovarian cancer medicine Lynparza (olaparib)
At the American Society of Clinical Oncology (ASCO) congress in Chicago this weekend, AstraZeneca presented results from a third interim analysis of Study 19 that suggest an improvement in overall survival (OS) for patients with ovarian cancer treated with Lynparza (olaparib) maintenance therapy following platinum-based chemotherapy.
AstraZeneca’s Faslodex for breast cancer shows positive results in Phase III trial
AstraZeneca has announced positive results from the Phase III FALCON trial comparing Faslodex 500mg (fulvestrant) to Arimidex 1mg (anastrozole) for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women who have not had prior hormonal treatment for hormone-receptor-positive (HR+) breast cancer.
AstraZeneca highlights continued progress of oncology pipeline at ASCO 2016
AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, on 3-7 June 2016.
AstraZeneca announces positive results for potential new medicine for asthma
AstraZeneca has announced that benralizumab, a potential new medicine and anti-eosinophil monoclonal antibody, was well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials (SIROCCO and CALIMA), demonstrating significant reductions in the annual asthma exacerbation rate compared to placebo.
Scientists publish discovery of novel protein associated with schizophrenia
Study results from scientists at AstraZeneca and the Lieber Institute for Brain Development indicate that the discovery of a recently evolved protein could lead to new targets for neuropsychiatric disorders and novel treatments for patients.
AstraZeneca launches integrated genomics approach to drug discovery and development
AstraZeneca and its global biologics research and development arm, MedImmune, today announced an integrated genomics initiative to transform drug discovery and development across its entire research and development pipeline.
AstraZeneca presents DNA Damage Response science at the AACR 2016 Annual Meeting
AstraZeneca has announced new data from multiple molecules in its industry-leading DNA Damage Response (DDR) pipeline at the 2016 American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA.
AstraZeneca showcases breadth of Oncology portfolio at AACR 2016 Annual Meeting
AstraZeneca and its global biologics research and development arm, MedImmune, will present 57 abstracts, deliver five oral presentations and two lectures as well as participating in a round-table session on PD-L1 diagnostic harmonisation at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans this week.
AstraZeneca and Eli Lilly continue clinical trial for people with early Alzheimer’s disease
AstraZeneca and Eli Lilly and Company today announced that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for early Alzheimer’s disease, will continue into Phase III of the Phase II/III seamless trial.
Brilique approved in EU for extended treatment of patients with history of heart attack
AstraZeneca today announced that the European Commission has granted marketing authorisation for Brilique (ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event.
AstraZeneca and MedImmune enter consortium to find new treatments for chronic kidney disease
AstraZeneca and its global biologics research and development arm, MedImmune, announced that they have entered into a collaboration with the University of Michigan and Eli Lilly to identify new therapeutic targets for the treatment of chronic kidney diseases (CKD).
AstraZeneca and MedImmune launch 'Science in pictures' artwork project at Cambridge site
AstraZeneca and MedImmune, the global biologics research and development arm of AstraZeneca, this week inaugurated “Science in pictures”, an artwork installation on the hoardings around the construction site of their new Research and Development Centre and Corporate Headquarters on the Cambridge Biomedical Campus.
AstraZeneca and Moderna Therapeutics announce new collaboration
AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics have announced a new collaboration to discover, co-develop and co-commercialise messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers.
AstraZeneca acquires Takeda’s respiratory business
AstraZeneca today announced that it has entered into a definitive agreement to acquire the core respiratory business of Takeda Pharmaceutical Company Limited. The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).
AstraZeneca to harness power of the Secretome and develop next-generation biologics
AstraZeneca and its global biologics research and development arm, MedImmune, today announced a three-year collaboration with the newly established Wallenberg Centre for Protein Research (WCPR). The collaboration aims to develop new technologies for biologics production and to identify new targets for disease research in the ground-breaking area of the Secretome - research into all proteins that…
AstraZeneca expands technological investment in new Cambridge lead discovery centre
AstraZeneca today announced three new partnerships that will deliver industry-leading technologies to drive the AstraZeneca MRC UK Centre for Lead Discovery in the search for novel small molecule medicines. The partnerships will ensure state-of-the-art screening and compound management at the facility, which will be located within the company’s new global R&D centre at the Cambridge Biomedical…
AstraZeneca acquires ZS Pharma
AstraZeneca announced today that it has entered into a definitive agreement to acquire ZS Pharma, a biopharmaceutical company based in San Mateo, California. The acquisition strengthens AstraZeneca's Cardiovascular and Metabolic disease portfolio.
AstraZeneca and Lilly expand immuno-oncology research collaboration with new combinations
AstraZeneca and Eli Lilly and Company (Lilly) have announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumours.